C32

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: C32
• 英文别名: 12-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-N,N-didecyldodecanamide
• 化学式: C₄₁H₈₂N₃O₃P
• 分子量: 696.094
• InChiKey: UYCLZLGMESIMJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.3
• 重原子数：
  48
• 可旋转键数：
  37
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  65.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  12-羟基十二酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 C32
  参考文献：
  名称：

  Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells

  摘要：

  Double-stranded short interfering RNAs (siRNAs) mediate post-transcriptional inhibition of gene expression in a variety of biological systems. However, human liver cells show poor uptake of these nucleic acids. In order to improve the delivery of siRNA into these cells without transfection agents, we have synthesized two series of lipophilic siRNAs conjugated with derivatives of cholesterol, lithocholic acid or lauric acid. The lipid moieties were covalently linked to the 5'-ends of the RNAs using phosphoramidite chemistry. The potency of these chemically modified siRNAs to inhibit reporter gene expression was further investigated in vitro with beta-galactosidase expressing liver cells. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.07.018

文献信息

• Lipophilic derivatives of double-stranded ribonucleic acid
  申请人：Alnylam Europe AG

  公开号：EP1852506A2

  公开（公告）日：2007-11-07

  The present invention relates to a double-stranded ribonucleic acid (dsRNA) having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA. The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at least a part of a target gene, and at least one covalently linked lipophilic group. The dsRNA are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.

  本发明涉及一种具有更高的基因表达抑制效率的双链核糖核酸(dsRNA)、制造这种dsRNA的方法以及包含这种dsRNA的药物组合物。dsRNA 包括一条 RNA 链（互补 RNA 链）和至少一个共价连接的亲脂基团，前者具有与靶基因至少一部分的 RNA 转录本互补的区域，后者具有与靶基因至少一部分的 RNA 转录本互补的区域。dsRNA 可用于抑制目的基因的表达，也可用于治疗由目的基因表达引起的疾病。本发明还涉及抑制目的基因表达的方法，以及治疗由基因表达引起的疾病的方法。
• LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID
  申请人：Alnylam Europe AG

  公开号：EP1587926A2

  公开（公告）日：2005-10-26
• [EN] LIPOPHILIC DERIVATIVES OF DOUBLE-STRANDED RIBONUCLEIC ACID<br/>[FR] DERIVES LIPOPHILES D'ACIDE RIBONUCLEIQUE A DOUBLE BRIN
  申请人：RIBOPHARMA AG

  公开号：WO2004065601A2

  公开（公告）日：2004-08-05

  The present invention relates to a double-stranded ribonucleic acid (dsRNA) having improved efficiency of inhibition of gene expression, methods of making the dsRNA, and pharmaceutical compositions comprising the dsRNA. The dsRNA comprises an RNA strand (complementary RNA strand) having a region which is complementary to an RNA transcript of at least a part of a target gene, and at least one covalently linked lipophilic group. The dsRNA are useful for inhibiting the expression of a target gene, as well as for treating diseases caused by expression of the target gene. The invention also relates to methods for inhibiting the expression of a target gene, as well as methods for treating diseases caused by the expression of the gene.
• Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells
  作者：Christina Lorenz、Philipp Hadwiger、Matthias John、Hans-Peter Vornlocher、Carlo Unverzagt

  DOI：10.1016/j.bmcl.2004.07.018

  日期：2004.10

  Double-stranded short interfering RNAs (siRNAs) mediate post-transcriptional inhibition of gene expression in a variety of biological systems. However, human liver cells show poor uptake of these nucleic acids. In order to improve the delivery of siRNA into these cells without transfection agents, we have synthesized two series of lipophilic siRNAs conjugated with derivatives of cholesterol, lithocholic acid or lauric acid. The lipid moieties were covalently linked to the 5'-ends of the RNAs using phosphoramidite chemistry. The potency of these chemically modified siRNAs to inhibit reporter gene expression was further investigated in vitro with beta-galactosidase expressing liver cells. (C) 2004 Elsevier Ltd. All rights reserved.